171 related articles for article (PubMed ID: 34647426)
21. Brigatinib versus crizotinib for ALK-positive NSCLC.
Stirrups R
Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790
[No Abstract] [Full Text] [Related]
22. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; García Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira A; Gettinger SN; Tiseo M; Lin HM; Gupta N; Hanley MJ; Ni Q; Zhang P; Popat S
J Clin Oncol; 2020 Nov; 38(31):3592-3603. PubMed ID: 32780660
[TBL] [Abstract][Full Text] [Related]
23. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY
J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596
[TBL] [Abstract][Full Text] [Related]
24. Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy.
Bronte G; Cafaro A; Pasini L; Priano I; Andrikou K; Cravero P; Burgio MA; Delmonte A; Crinò L
Expert Rev Anticancer Ther; 2021 Aug; 21(8):809-817. PubMed ID: 33905667
[No Abstract] [Full Text] [Related]
25. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Takahashi K; Seto Y; Okada K; Uematsu S; Uchibori K; Tsukahara M; Oh-Hara T; Fujita N; Yanagitani N; Nishio M; Okubo K; Katayama R
Thorac Cancer; 2020 Mar; 11(3):581-587. PubMed ID: 31943796
[TBL] [Abstract][Full Text] [Related]
26. A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.
Sharma GG; Cortinovis D; Agustoni F; Arosio G; Villa M; Cordani N; Bidoli P; Bisson WH; Pagni F; Piazza R; Gambacorti-Passerini C; Mologni L
J Thorac Oncol; 2019 Nov; 14(11):e257-e259. PubMed ID: 31668326
[No Abstract] [Full Text] [Related]
27. Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.
Gaye E; Geier M; Bore P; Guilloïque M; Lucia F; Quéré G; Gouva S; Robinet G; Descourt R
Lung Cancer; 2019 Jul; 133():1-3. PubMed ID: 31200813
[TBL] [Abstract][Full Text] [Related]
28. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
29. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
Lin JJ; Zhu VW; Schoenfeld AJ; Yeap BY; Saxena A; Ferris LA; Dagogo-Jack I; Farago AF; Taber A; Traynor A; Menon S; Gainor JF; Lennerz JK; Plodkowski AJ; Digumarthy SR; Ou SI; Shaw AT; Riely GJ
J Thorac Oncol; 2018 Oct; 13(10):1530-1538. PubMed ID: 29935304
[TBL] [Abstract][Full Text] [Related]
30. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
[TBL] [Abstract][Full Text] [Related]
32. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease.
Doménech M; Jové M; Aso S; Marín M; Nadal E
Lung Cancer; 2018 May; 119():99-102. PubMed ID: 29656760
[TBL] [Abstract][Full Text] [Related]
34. Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
Nishio M; Yoshida T; Kumagai T; Hida T; Toyozawa R; Shimokawaji T; Goto K; Nakagawa K; Ohe Y; Seto T; Kudou K; Asato T; Zhang P; Yamamoto N
J Thorac Oncol; 2021 Mar; 16(3):452-463. PubMed ID: 33248320
[TBL] [Abstract][Full Text] [Related]
35. Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer.
Spencer SA; Riley AC; Matthew A; Di Pasqua AJ
Ann Pharmacother; 2019 Jun; 53(6):621-626. PubMed ID: 30638036
[TBL] [Abstract][Full Text] [Related]
36. Clinical consequences of resistance to
Pinto JA; Raez LE; Domingo G
Expert Rev Respir Med; 2020 Apr; 14(4):385-390. PubMed ID: 31971859
[No Abstract] [Full Text] [Related]
37. Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.
Hochmair M; Weinlinger C; Schwab S; Naber J; Setinek U; Krenbek D; Urban MH; Fabikan H; Watzka S; Koger R; Fazekas A; Bitterlich E; Valipour A; Burghuber OC
Anticancer Drugs; 2019 Aug; 30(7):e0787. PubMed ID: 31305295
[TBL] [Abstract][Full Text] [Related]
38. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).
Garcia Campelo MR; Lin HM; Zhu Y; Pérol M; Jahanzeb M; Popat S; Zhang P; Camidge DR
Lung Cancer; 2021 May; 155():68-77. PubMed ID: 33744781
[TBL] [Abstract][Full Text] [Related]
39. Brigatinib for
Ali R; Arshad J; Palacio S; Mudad R
Drug Des Devel Ther; 2019; 13():569-580. PubMed ID: 30804663
[TBL] [Abstract][Full Text] [Related]
40. Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC.
Stinchcombe TE; Doebele RC; Wang X; Gerber DE; Horn L; Camidge DR
J Thorac Oncol; 2021 Jan; 16(1):156-161. PubMed ID: 33039599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
